Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6269354 | 0.95 | ACHE (0.68) | ACHEEPHX2 | |
| SCHEMBL8086226 | 0.93 | ACHE (0.62) | ACHEEPHX2 | |
| SCHEMBL29991047 | 0.93 | ACHE (0.71) | ACHEEPHX2 | |
| SCHEMBL721691 | 0.93 | ACHE (0.71) | ACHEEPHX2 | |
| SCHEMBL4736241 | 0.93 | ACHE (0.71) | ACHEEPHX2 | |
| SCHEMBL7677452 | 0.93 | ACHE (0.71) | ACHEEPHX2 | |
| SCHEMBL6950987 | 0.93 | ACHE (0.71) | ACHEEPHX2 | |
| SCHEMBL29728302 | 0.92 | ACHE (0.60) | ACHEEPHX2 | |
| SCHEMBL3900003 | 0.91 | ACHE (0.66) | ACHE | |
| SCHEMBL855002 | 0.91 | ACHE (0.67) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106670-A1 | IONIZABLE LIPIDOID COMPOSITIONS AND THERAPEUTIC USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| EP-1301464-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | disclosed |
| EP-0898596-A1 | SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD | Amersham Pharmacia Biotech UK Limited (GB) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040104-A1 | SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ACHE 2562/4885EPHX2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.